

Figure 1

09976596-101201




Figure 2






Figure 5




FIGURE 6




Figure 7

FOOT-5652660




Figure 8

FOOTNOTES: 9653/650







Figure 10

LN size post-HSV inoculation

LN cell
number
(x 10⁻⁶)



Activated cell numbers

activated
cells
(x10⁻⁴)






Figure 11

0976596-10201


0996596-10104
F02F01-96594660



2 months



18 months



18 months
Castrated

Figure 12






FIGURE 13

0997559-10161




FIGURE 14




FIGURE 15





Figure 16

A.



B.




FIGURE 17

FOOTNOTES 96594660





FIGURE 18

A.



B.




FIGURE 19

FOR FOT 36592660




FIGURE 20




FIGURE 21




FIGURE 22




FIGURE 23

FOOT-36592660





FIGURE 24




FIGURE 25

cells/mL
blood
(x10)




FIGURE 26





FIGURE 27

% of total
peripheral
blood
lymphocytes



□ Control □ Pre-LHRH-A treatment ■ 4 months of LHRH-A treatment

FIGURE 28




FIGURE 29





FIGURE 30




FIGURE 31

102701-96592660




FIGURE 32




FIGURE 33




FIGURE 34

FOOT" 96592660




FIGURE 35

FOOT " 91594660